March 11, 2024 04:08 PM EDTUpdated 05:20 PM
Pharma

CBO hints that Medicare may soon cov­er obe­si­ty drugs for their car­dio­vas­cu­lar ben­e­fits

Zachary Brennan

Senior Editor

Medicare is star­ing down tens of bil­lions of dol­lars in fu­ture ex­pens­es if it be­gins cov­er­ing obe­si­ty drugs like No­vo Nordisk’s We­govy and Eli Lil­ly’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times